News | January 08, 2026
Arrowhead Pharmaceuticals gets green light for first-of-its-kind FCS therapy
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety
Sovaaka offers a deeply personalised diagnostics-led wellness experience that goes beyond routine health checks
_256_384.jpg){kind=logo}
Fasting glucose improved by 12.3 mg/dL, while liver stiffness dropped 23.7%, signaling a direct hepatic benefit
Heart failure affects an estimated 64.3 million people worldwide
WuXi Biologics has integrated sustainability principles throughout its supplier lifecycle management
The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
The approval is supported by data from three pivotal clinical trials
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
Subscribe To Our Newsletter & Stay Updated
